Valuation: Orion Oyj

Market Cap 9.92B 11.32B 9.13B 8.48B 16.1B 1,080B 16.32B 109B 42.54B 530B 42.52B 41.58B 1,838B P/E 2026 *
18x
P/E 2027 * 15.3x
Enterprise Value 9.81B 11.21B 9.04B 8.39B 15.93B 1,069B 16.15B 108B 42.11B 525B 42.09B 41.16B 1,819B EV / Sales 2026 *
4.72x
EV / Sales 2027 * 4.08x
Free-Float
90.5%
Yield 2026 *
2.7%
Yield 2027 * 3%
1 day+4.81%
6 months+1.78%
Current year+1.78%
Current year 78.95
Extreme 78.95
82.75
1 year 78.95
Extreme 78.95
82.75
3 years 37
Extreme 37
82.75
5 years 37
Extreme 37
82.75
10 years 27.35
Extreme 27.35
82.75
Manager TitleAgeSince
Chief Executive Officer 59 2022-10-31
Director of Finance/CFO 50 2024-04-30
Chief Operating Officer 46 2021-12-31
Director TitleAgeSince
Director/Board Member 63 2017-03-21
Director/Board Member 65 2017-03-21
Director/Board Member 66 2020-05-05
Change 5-day change 1-year change 3-year change Capi.($)
+4.81%-.--% - - 11.59B
-1.14%-2.43%+53.72%+159.07% 1,082B
-1.41%+0.32%+66.23%+60.48% 633B
-2.42%+0.18%+34.59%+85.62% 461B
-0.26%+0.53%+31.00%+25.82% 338B
-2.46%-1.38%+36.42%+36.52% 299B
-2.20%-0.87%+27.50%+42.69% 291B
-1.77%+1.97%-28.85%-40.66% 222B
-2.06%+1.63%+22.87%+64.34% 202B
-1.26%+2.60%+15.98%+70.00% 163B
Average -1.02%+0.62%+28.83%+55.99% 410.27B
Weighted average by Cap. -1.53%-0.22%+39.61%+80.57%

Financials

2026 *2027 *
Net sales 2.08B 2.38B 1.92B 1.78B 3.38B 227B 3.42B 22.94B 8.93B 111B 8.92B 8.73B 386B 2.35B 2.69B 2.17B 2.01B 3.82B 256B 3.87B 25.93B 10.09B 126B 10.08B 9.86B 436B
Net income 550M 627M 506M 470M 892M 59.85B 904M 6.06B 2.36B 29.38B 2.36B 2.3B 102B 649M 741M 598M 555M 1.05B 70.7B 1.07B 7.16B 2.79B 34.71B 2.78B 2.72B 120B
Net Debt -101M -115M -92.7M -86.05M -163M -10.96B -166M -1.11B -432M -5.38B -432M -422M -18.66B -313M -357M -288M -267M -508M -34.06B -515M -3.45B -1.34B -16.72B -1.34B -1.31B -57.97B
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
4,132
Date Price Change Volume
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
70.50EUR
Average target price
74.33EUR
Spread / Average Target
+5.44%

Quarterly revenue - Rate of surprise